

6 State of New Product Development (As of July 26, 2021)

(1) Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Bipolar disorder)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Filed	Licensed from Horizon Therapeutics (Ireland)
	(Myasthenia gravis)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Filed (Apr. 2021)	Licensed from Neurocrine Biosciences (US)
		Asia Filed	
MT-210 (Roluperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921	Anti-RGMA antibody (Spinal cord injury)	Phase 1	Co-developed with Osaka University (Japan)

(2) Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
	(Systemic sclerosis)	Global Phase 2	
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (IgG4-related disease)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house

※ Asia: Excluding Japan and China

(3) Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2271	Plant-based VLP vaccine (Prophylaxis of seasonal influenza/adults)	Canada Filed (Sep. 2019)	Medicago product (Canada)
	(Prophylaxis of seasonal influenza/elderly)	Europe Phase 3	
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	Global Phase 3	Medicago product (Canada)
MT-8972	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-based VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2654	Adjuvanted plant-based VLP vaccine (Prophylaxis of seasonal influenza/elderly)	Phase 1	Medicago product (Canada)

(4) Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
		China Filed (Sep. 2019)	
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Japan Phase 3	In-house
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-2765	Renin inhibitor (Hypertension)	China Phase 3	Licensed to Shanghai Pharmaceuticals (China)
MT-8633/TR1801-ADC	Anti-c-Met ADC* (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

*Antibody drug conjugate

※ Asia: Excluding Japan and China

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of July 26, 2021	Origin/Licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	Thailand Approved (Apr. 2021)	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Indonesia Approved (July 2021)	Licensed from Gedeon Richter (Hungary)
	(Bipolar disorder)	None	Asia Filed	
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Asia Filed	Singapore Approved (May 2021)	Licensed from Neurocrine Biosciences (US)
MT-2765	Renin inhibitor (Hypertension)	None	China Phase 3	Licensed to Shanghai Pharmaceuticals (China)
MT-3995 (Apararenone)	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe Phase 2	Deleted (Discontinued)	In-house
		Japan Phase 2		
	(Non-alcoholic steatohepatitis: NASH)	Japan Phase 2		

※ Asia: Excluding Japan and China